Literature DB >> 25842219

M2e-immobilized gold nanoparticles as influenza A vaccine: Role of soluble M2e and longevity of protection.

Wenqian Tao1, Harvinder S Gill2.   

Abstract

Influenza virus causes seasonal epidemics and also poses a high risk for pandemics. To develop a broadly cross-protective influenza vaccine we have previously shown that a formulation consisting of the extracellular domain of M2 membrane protein (M2e) immobilized on gold nanoparticles (AuNPs) and soluble CpG as an adjuvant can elicit protective immunity against different influenza A subtypes. The vaccine formulation contains M2e that is immobilized on AuNPs, and an excess amount that is freely dissolved in solution, whose role in inducing protective immunity against virus infection is unclear. Using a mouse model, the current study shows that inclusion of excess soluble M2e antigen along with M2e immobilized on AuNPs is vital for inducing high levels of antibody response, and in providing complete protection against lethal influenza virus challenge. We also show that the vaccine induces long-lasting protection against mortality and morbidity upon lethal challenge with influenza A virus.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Influenza; Long-term protection; Nanoparticle-conjugated M2e; Soluble M2e; Universal vaccine

Mesh:

Substances:

Year:  2015        PMID: 25842219      PMCID: PMC4418433          DOI: 10.1016/j.vaccine.2015.03.063

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  39 in total

1.  Rational and combinatorial design of peptide capping ligands for gold nanoparticles.

Authors:  Raphaël Lévy; Nguyen T K Thanh; R Christopher Doty; Irshad Hussain; Richard J Nichols; David J Schiffrin; Mathias Brust; David G Fernig
Journal:  J Am Chem Soc       Date:  2004-08-18       Impact factor: 15.419

Review 2.  Avian influenza A (H5N1) infection in humans.

Authors:  John H Beigel; Jeremy Farrar; Aye Maung Han; Frederick G Hayden; Randy Hyer; Menno D de Jong; Sorasak Lochindarat; Thi Kim Tien Nguyen; Tran Hien Nguyen; Tinh Hien Tran; Angus Nicoll; Sok Touch; Kwok-Yung Yuen
Journal:  N Engl J Med       Date:  2005-09-29       Impact factor: 91.245

3.  Assembly and characterization of biomolecule-gold nanoparticle conjugates and their use in intracellular imaging.

Authors:  Alexander Tkachenko; Huan Xie; Stefan Franzen; Daniel L Feldheim
Journal:  Methods Mol Biol       Date:  2005

4.  Development of effective vaccines against pandemic influenza.

Authors:  Kanta Subbarao; Brian R Murphy; Anthony S Fauci
Journal:  Immunity       Date:  2006-01       Impact factor: 31.745

5.  Biodistribution of colloidal gold nanoparticles after intravenous administration: effect of particle size.

Authors:  Ganeshchandra Sonavane; Keishiro Tomoda; Kimiko Makino
Journal:  Colloids Surf B Biointerfaces       Date:  2008-07-15       Impact factor: 5.268

Review 6.  Virus-induced humoral immunity: on how B cell responses are initiated.

Authors:  Franziska Zabel; Thomas M Kündig; Martin F Bachmann
Journal:  Curr Opin Virol       Date:  2013-06-01       Impact factor: 7.090

7.  Plasmacytoid dendritic cells, antigen, and CpG-C license human B cells for plasma cell differentiation and immunoglobulin production in the absence of T-cell help.

Authors:  Hendrik Poeck; Moritz Wagner; Julia Battiany; Simon Rothenfusser; Daniela Wellisch; Veit Hornung; Bernd Jahrsdorfer; Thomas Giese; Stefan Endres; Gunther Hartmann
Journal:  Blood       Date:  2003-12-30       Impact factor: 22.113

8.  Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys.

Authors:  Jiang Fan; Xiaoping Liang; Melanie S Horton; Helen C Perry; Michael P Citron; Gwen J Heidecker; Tong-Ming Fu; Joseph Joyce; Craig T Przysiecki; Paul M Keller; Victor M Garsky; Roxana Ionescu; Yvette Rippeon; Li Shi; Michael A Chastain; Jon H Condra; Mary-Ellen Davies; Jason Liao; Emilio A Emini; John W Shiver
Journal:  Vaccine       Date:  2004-08-13       Impact factor: 3.641

9.  Design of a protective single-dose intranasal nanoparticle-based vaccine platform for respiratory infectious diseases.

Authors:  Bret D Ulery; Devender Kumar; Amanda E Ramer-Tait; Dennis W Metzger; Michael J Wannemuehler; Balaji Narasimhan
Journal:  PLoS One       Date:  2011-03-03       Impact factor: 3.240

10.  M2e-displaying virus-like particles with associated RNA promote T helper 1 type adaptive immunity against influenza A.

Authors:  Lorena Itatí Ibañez; Kenny Roose; Marina De Filette; Michael Schotsaert; Jessica De Sloovere; Stefan Roels; Charlotte Pollard; Bert Schepens; Johan Grooten; Walter Fiers; Xavier Saelens
Journal:  PLoS One       Date:  2013-03-18       Impact factor: 3.240

View more
  28 in total

1.  Immune Response of Mice Against Babesia canis Antigens is Enhanced When Antigen is Coupled to Gold Nanoparticles.

Authors:  S A Staroverov; A S Fomin; S V Kozlov; A A Volkov; E S Kozlov; K P Gabalov; L A Dykman
Journal:  Acta Parasitol       Date:  2020-11-09       Impact factor: 1.440

2.  Investigation of tunable acetalated dextran microparticle platform to optimize M2e-based influenza vaccine efficacy.

Authors:  Naihan Chen; Matthew D Gallovic; Pamela Tiet; Jenny P-Y Ting; Kristy M Ainslie; Eric M Bachelder
Journal:  J Control Release       Date:  2018-09-24       Impact factor: 9.776

Review 3.  Mucosal vaccine delivery: Current state and a pediatric perspective.

Authors:  Akhilesh Kumar Shakya; Mohammed Y E Chowdhury; Wenqian Tao; Harvinder Singh Gill
Journal:  J Control Release       Date:  2016-02-06       Impact factor: 9.776

4.  Consensus M2e peptide conjugated to gold nanoparticles confers protection against H1N1, H3N2 and H5N1 influenza A viruses.

Authors:  Wenqian Tao; Brett L Hurst; Akhilesh Kumar Shakya; Md Jasim Uddin; Rohan S J Ingrole; Mayra Hernandez-Sanabria; Ravi P Arya; Lynn Bimler; Silke Paust; E Bart Tarbet; Harvinder Singh Gill
Journal:  Antiviral Res       Date:  2017-02-02       Impact factor: 5.970

5.  Current Prospects in Peptide-Based Subunit Nanovaccines.

Authors:  Prashamsa Koirala; Sahra Bashiri; Istvan Toth; Mariusz Skwarczynski
Journal:  Methods Mol Biol       Date:  2022

6.  Tyrosine-Based Cross-Linking of Peptide Antigens to Generate Nanoclusters with Enhanced Immunogenicity: Demonstration Using the Conserved M2e Peptide of Influenza A.

Authors:  Logan R Wilks; Gaurav Joshi; Megan R Grisham; Harvinder Singh Gill
Journal:  ACS Infect Dis       Date:  2021-08-25       Impact factor: 5.578

Review 7.  Novel approaches for vaccine development.

Authors:  Makda S Gebre; Luis A Brito; Lisa H Tostanoski; Darin K Edwards; Andrea Carfi; Dan H Barouch
Journal:  Cell       Date:  2021-03-18       Impact factor: 41.582

Review 8.  Nanoparticle vaccines against respiratory syncytial virus.

Authors:  Laura M Stephens; Steven M Varga
Journal:  Future Virol       Date:  2020-11-30       Impact factor: 1.831

Review 9.  Use of Protamine in Nanopharmaceuticals-A Review.

Authors:  Ivana Ruseska; Katja Fresacher; Christina Petschacher; Andreas Zimmer
Journal:  Nanomaterials (Basel)       Date:  2021-06-07       Impact factor: 5.076

10.  M2e conjugated gold nanoparticle influenza vaccine displays thermal stability at elevated temperatures and confers protection to ferrets.

Authors:  Rohan S J Ingrole; Wenqian Tao; Gaurav Joshi; Harvinder Singh Gill
Journal:  Vaccine       Date:  2021-07-21       Impact factor: 4.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.